Tirzepatide for Obesity Treatment and Diabetes Prevention
The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease and causal precursor to myriad other conditions, including type 2 diabetes. In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial and sustained reductions in body weight in persons with obesity over a 72-week period. Here, we report the 3-year safety outcomes with tirzepatide and its efficacy in reducing weight and delaying progression to type 2 diabetes in persons with both obesity and prediabetes. METHODS: We performed a phase 3, double-blind, randomized, controlled trial in which 2539 participants with obesity, of whom 1032 also had prediabetes, were assigned in a 1:1:1:1 ratio to receive tirzepatide at a once-weekly dose of 5 mg, 10 mg, or 15 mg or placebo. The current analysis involved the participants with both obesity and prediabetes, who received their assigned dose of tirzepatide or placebo for a total of 176 weeks, followed by a 17-week off-treatment period. The three key secondary end points, which were controlled for type I error, were the percent change in body weight from baseline to week 176 and onset of type 2 diabetes during the 176-week and 193-week periods. RESULTS: At 176 weeks, the mean percent change in body weight among the participants who received tirzepatide was -12.3% with the 5-mg dose, -18.7% with the 10-mg dose, and -19.7% with the 15-mg dose, as compared with -1.3% among those who received placebo (P<0.001 for all comparisons with placebo). Fewer participants received a diagnosis of type 2 diabetes in the tirzepatide groups than in the placebo group (1.3% vs. 13.3%; hazard ratio, 0.07; 95% confidence interval [CI], 0.0 to 0.1; P<0.001). After 17 weeks off treatment or placebo, 2.4% of the participants who received tirzepatide and 13.7% of those who received placebo had type 2 diabetes (hazard ratio, 0.12; 95% CI, 0.1 to 0.2; P<0.001). Other than coronavirus disease 2019, the most common adverse events were gastrointestinal, most of which were mild to moderate in severity and occurred primarily during the dose-escalation period in the first 20 weeks of the trial. No new safety signals were identified. CONCLUSIONS: Three years of treatment with tirzepatide in persons with obesity and prediabetes resulted in substantial and sustained weight reduction and a markedly lower risk of progression to type 2 diabetes than that with placebo. (Funded by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“prediabetes to type 2 diabetes by 66-93% compared with placebo.65,75,76”
From GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits (2026) · cites this paper as [76]
In the citing paper
“Tirzepatide administered at doses of 5, 10, and 15 mg once weekly in adjunct with a behavioral intervention comprising an energy-deficit diet and increased physical activity appears to be even more effective, with absolute weight losses of 15.0%, 19.5%, and 20.9% after 72 weeks in the SURMOUNT-1 trial 31 that was largely maintained when treatment was continued in a subset of participants for 176”
From The societal implications of using glucagon-like peptide-1 receptor agonists for the treatment of obesity (2025) · cites this paper as [32]
In the citing paper
“SURMOUNT-1 showed the NNT with tirzepatide to prevent one case of T2D was 9 patients.”
From The societal implications of using glucagon-like peptide-1 receptor agonists for the treatment of obesity (2025) · cites this paper as [32]
In the citing paper
“This stepwise approach anchored in trial evidence strengthens confidence in the validity and applicability of the current results, reinforcing the role of GLP-1-based therapies beyond previously established benefits in the evolving management of cardiometabolic HFpEF.54,56-62”
From Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction (2025) · cites this paper as [62]
In the citing paper
“the reversal in glycemic benefits in HbA1c and FSG were observed early on within 16 weeks of withdrawing tirzepatide likely due to the known direct glucose-lowering effect of tirzepatide”
From Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial (2026) · cites this paper as [18]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Self-citationSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Self-citation2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Phelps, N. H., Singleton, R. K., Zhou, B., Heap, R. A., Mishra, A., Bennett, J. E., Paciorek, C. J., Lhoste, V. P., Carrillo-Larco, R. M., Stevens, G. A., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(23)02750-2 · Cited by 2,544
Self-citationLean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33102-1 · Cited by 2,095
Cited by
Items 201–300 of 443
Wharton, S., Stefański, A., Chen, J., Rao, G. S., Twum, E. A., & Denning, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71032 · Cited by 3
Self-citationGLP-1-based combination strategies for weight loss: Multi-target agents and combination therapies
Wang, X., Lin, R., Sun, Q., Xin, X., & Feng, Q. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108331 · Cited by 2
Sleep and obesity—known interactions and open questions
Schmickl, C. N., Gomez, R., Sunwoo, B. Y., Mesarwi, O. A., Kumar, A., & Malhotra, A. (2026) · Journal of Clinical Sleep Medicine · doi:10.1007/s44470-026-00130-7 · Cited by 3
“Incretin-based therapies, including dual GIP/GLP-1 receptor agonists such as tirzepatide, lower the defended fat mass set point, producing substantial and sustained weight loss and reframing obesity as a biologically treatable condition [24].”
Bile acids and incretins as modulators of obesity-associated atherosclerosis
Kirsch, A., Gindlhuber, J., Zabini, D., & Osto, E. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1510148 · Cited by 3
Khan, T., Zasadzinski, L., Owen, A. L., Vargas, M. C., & O’Brien, M. J. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09459-w · Cited by 2
“34,35 Given their high cost, it is likely that uptake of these newer medications will be slow among FQHC patients.”
Medikamentöse Adipositastherapie in Deutschland
Blüher, M. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01897-2 · Cited by 4
Fadini, G. P. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01759-y · Cited by 3
“…claimed to mediate the impact of obesity on glucose metabolism by affecting beta-cell function [2, 3]. the tirzepatide group progressed to diabetes [4], resulting in an estimated rate of 32.5 per 1000 patient-years—a rate similar to that observed in the placebo group during the entire study period…”
InfluentialWang, S., Fan, D., Yao, Q., & Sun, X. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16580 · Cited by 3
“47 50 Tirzepatide administered at doses of 10 and 15 mg is associated with a higher risk of premature discontinuation compared with semaglutide 1 mg, 14 which has important ramifications for both clinical practice and economic assessment.”
Sardà, H., Genua, I., & Miñambres, I. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2025.106951 · Cited by 4
The past and future of obesity research
Blüher, M. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01172-2 · Cited by 4
“So far, tirzepatide provides the highest magnitude of weight loss among anti-obesity medications, with an average weight loss of >20% at the highest dose (15 mg once weekly) that could be sustained over 3 years in the context of the SURMOUNT-1 trial 7 .”
Taha, M. M. E., Abdelwahab, S. İ., Oraibi, O., Madkhali, M. A., Alhazmi, A., Jeraiby, M., Abdullah, S. M., Farasani, A. M., Moshi, J. M., Khamjan, N. A., et al. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04574-1 · Cited by 3
Schmickl, C. N., Tripipitsiriwat, A., Mokhlesi, B., et al. (2025) · medRxiv · doi:10.1101/2025.10.02.25337176 · Cited by 2
“In the SURMOUNT trials [24 , 25 , 30 ], one year of tirzepatide led to ~ 20% weight loss, which in the SURMOUNT-OSA study [ 25] translated to a ~ 55% reduction in OSA sever - ity.”
Piťhová, P. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.009 · Cited by 1
Maki, K. C., Kirkpatrick, C. F., & Almandoz, J. P. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.02.019 · Cited by 1
Beta-cell preservation in T2DM using a pathophysiologic approach
Papatheodorou, K., & Shubrook, J. H. (2025) · Postgraduate Medicine · doi:10.1080/00325481.2025.2494502 · Cited by 3
“Participants were treated with tirzepatide once-weekly dosing of 5 mg, 10 mg, 15 mg, or placebo for 176 weeks, followed by a 17-week off-treatment period, to evaluate its efficacy in weight reduction and delaying progression to T2DM [40].”
InfluentialFármacos basados en GLP-1: mecanismos implicados en el tratamiento de la obesidad
Salvador, J. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107035 · Cited by 13
Blüher, M. (2025) · Herz · doi:10.1007/s00059-025-05321-1 · Cited by 1
Corbalan, J. J., Petronella, B. A., Huang, C., Beasley, J. R., Merritt, J. R., Mugrage, B., & Nickels, J. T. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152360 · Cited by 1
Extinguishing the Fire: Treating Pediatric Type 2 Diabetes by Targeting Obesity Treatment
Bensignor, M. O., Hsia, D. S., Name, M. A. V., Jastreboff, A. M., & Ryder, J. R. (2025) · Diabetes Care · doi:10.2337/dci25-0031 · Cited by 2
Self-citationCardiovascular Benefits of Glucagon-Like Peptide-1 Receptor Agonists
Tran-Duc, P. N., & Heo, K. (2025) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2025.5.e9 · Cited by 4
Akwe, J. A., Fongeh, K., Jung, S. A., Hall, M. A. K., Patidar, V., & Shin, Y. M. (2025) · Cureus · doi:10.7759/cureus.91677 · Cited by 5
Tirzepatide, Mortality, Cardiovascular, and Renal Outcomes in Sleep Apnea
Mazzotti, D. R., & Stevens, D. R. (2025) · CHEST Journal · doi:10.1016/j.chest.2025.05.019 · Cited by 1
Ramos, M., Larsen, S., Fusco, F., Lamotte, M., & Capehorn, M. (2025) · Journal of Medical Economics · doi:10.1080/13696998.2025.2575692 · Cited by 3
EndoCompass project: research roadmap for diabetes, obesity, and metabolism
Mathieu, C., Meireles, M., Pagotto, U., Wabitsch, M., Banerjee, I., Bartolomé, A., Battelino, T., Beck, J., Chiarelli, F., León, D. D. D., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf065 · Cited by 5
Scilletta, S., Welsh, P. I., Pino, A. D., & Sattar, N. A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70248 · Cited by 2
Hussain, M., & Miras, A. D. (2025) · Die Chirurgie · doi:10.1007/s00104-025-02402-z · Cited by 3
Effect of GLP ‐1 receptor agonists on idiopathic intracranial hypertension: A systematic review
de Oliveira, H. M., Ruelas, M. G., Fonseca, P. E. O., Diaz, C. A. V., de Paula, G. O., da Costa, P. R. F., Parker, T., & Kahle, K. T. (2025) · Headache The Journal of Head and Face Pain · doi:10.1111/head.70005 · Cited by 5
Standl, E., Ceriello, A., McGuire, D. K., Schnell, O., & Holman, R. R. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02959-3 · Cited by 3
“…by bariatric surgery [59, 60], followed by studies successfully exercising comprehensive and rigid life style management, e.g. the DiRECT study [63], and most recently seen with GLP1-RAs or co-agonists like semaglutide and tirzepatide with the development of further co-agonists pending [61, 62].”
Saraiva, J. F. K., Valério, C. M., Rached, F. H., van de Sande‐Lee, S., Rocha, V. Z., Valente, F., Drager, L. F., Halpern, B., Júnior, W. S. D. S., Trujilho, F. R., et al. (2025) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20250621 · Cited by 17
Self-citationSzewczyk, A., Tobiasz-Kałkun, N., Stefanowicz, A., Kobos, E., Kapuściok, J., Karczewska, A., Mazuryk, K., & Hornik, B. (2025) · Pielegniarstwo XXI wieku / Nursing in the 21st Century · doi:10.12923/pielxxiw-2025-0034 · Cited by 2
Wu, R., Xing, B., Zhou, Z., Yu, L., & Wang, H. (2025) · Neurological Sciences · doi:10.1007/s10072-025-08680-z · Cited by 1
Saeed, Z. I., & Apovian, C. M. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01369-w · Cited by 2
“This signified the num - ber needed to treat [NNT] to be 8 over 3.4 years [ 56 ].”
InfluentialThiyagarajan, S. K., Wall‐Wieler, E., Liu, Y., Zheng, F., & Edwards, M. (2026) · Obesity Surgery · doi:10.1007/s11695-025-08467-3 · Cited by 2
Navigating the benefits and harms of GLP-1 and GLP-1/GIP agonists in obesity
O'Connor, R. G. (2026) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2025.000039 · Cited by 2
Ishigaki, Y., Yamada, M., Shingaki, T., Oura, T., & Shimomura, I. (2026) · Obesity · doi:10.1002/oby.70131 · Cited by 2
“In addition, 3-year efficacy and safety analyses of the global SURMOUNT-1 trial revealed substantial and sustained weight reduction and a markedly lower risk of progression to T2D with tirzepatide treatment compared with placebo in participants with obesity and prediabetes [27].”
Lapsiwala, B. J., Nathani, P. S., Bhalodia, A. R., Rangan, A., Rajpopat, P. B., Khan, F., Vaghani, U., Kanagala, S. G., Chandramohan, D., Naik, R., et al. (2026) · Postgraduate Medical Journal · doi:10.1093/postmj/qgag009 · Cited by 2
Chen, Q., Chen, T., Lin, W., & Chen, X. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s585436 · Cited by 3
“10,11 They stand in stark contrast to their short-acting counterparts, which zero in on postprandial glucose excursions.”
CYRANKA, K. M., Snoek, F. J., Hermanns, N., Ehrmann, D., & Klupa, T. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70549 · Cited by 2
“15,16 While these therapies offer hope, they may also introduce new psychological tensions, including fear of side effects, anxiety about treatment discontinuation and weight regain and internalised beliefs that pharmacological support represents a ‘ shortcut ’ rather than a legitimate medical…”
Warden, B. A., Duell, P. B., Bucheit, J. D., & Purnell, J. Q. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.11.013 · Cited by 1
The association of obesity with cardiovascular disease risk and risk-enhancing factors
Paparodis, R. D., Bantouna, D., Livadas, S., & Angelopoulos, N. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.08.018 · Cited by 6
Incretin Mimetics in Cancer and Cardiovascular Disease
Leong, D. P., Gong, S., Sattar, N. A., Narayan, V., Reizine, N. M., Gerstein, H. C., & Vellky, J. E. (2026) · JACC CardioOncology · doi:10.1016/j.jaccao.2025.12.003 · Cited by 3
Jayathilaka, N. S., Wijekoon, K. J., Sachinthani, S. D. D., Weththasinghe, A. V., Ganamurali, N., & Sabarathinam, S. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-01887-7 · Cited by 2
“Longer-term follow-up studies further indicate that weight reduction is maintained during continued therapy, although attenuation of effect and weight regain may occur following dose reduction or discontinuation [82].”
Gonçalves, J., Ferreira, H. U., Menino, J., Meira, I., Ribeiro, S., Moreno, T., Leite, A. R., Ferreira, P., Costa, T., Borges-Canha, M., et al. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02039-w · Cited by 2
“Despite these limitations, the extended follow-up period and the uniform care provided by a dedicated multidisciplinary team strengthen our conclusions and provide valuable long-term data for the Portuguese population.”
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1445 · Cited by 1
Self-citationTroshina, E. A., Suplotova, L. A., Dzgoeva, F. K., Ekusheva, E. V., Vyuchnova, E. S., Okovityi, S. V., Bakulin, I. G., Бакулина, Н. В., Karonova, T. L., Vagapova, G. R., et al. (2026) · Problems of Endocrinology · doi:10.14341/probl13737 · Cited by 1
“Это предоставляет вра-чу возможность выбора конечной дозы в зависимости от индивидуальных целей терапии и переносимости [10].”
The Fatty Pancreas: Current Evidence, Treatment Implications, and Future Directions
Syed, K. A., Manoj, M. A., Forsmark, C. E., Hughes, S. J., Grajo, J. R., Feely, M. M., & Novikov, A. A. (2026) · Gastro Hep Advances · doi:10.1016/j.gastha.2026.100933 · Cited by 4
Benny, O., Agarwal, A., Alecock, H., Subramani, R. G., Pawar, A., Shams, Z., Kermansaravi, M., Pouwels, S., Yang, W., Gerald, C., et al. (2026) · Pancreatology · doi:10.1016/j.pan.2026.03.021 · Cited by 6
Tirzepatide in Metabolic Diseases: Clinical Efficacy and Safety Beyond Diabetes and Obesity
Dong, S., Xu, Y., Gan, R., Zhang, A., He, J., & Tang, Q. (2026) · Medicinal Research Reviews · doi:10.1002/med.70049 · Cited by 1
The Epidemiology, Prevention, and Control of Type 2 Diabetes in Low- and Middle-Income Countries
Kocher, E. L., Teufel, F., Carrillo-Larco, R. M., Chakkalakal, R. J., & Ali, M. K. (2026) · Annual Review of Public Health · doi:10.1146/annurev-publhealth-081624-060046 · Cited by 3
Gouda, P., Allyn, N., Belin, R. M., Borentain, M., Butler, J., Curtis, L. H., George, J. T., Hornik, C. P. V., Jackman, J. G., Jessup, M. L., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.102713 · Cited by 2
Self-citationGLP-1 medications for weight-loss: a triumph of marketing over patient care
Chastain, R., Meadows, A., & Adams, L. (2026) · Fat Studies · doi:10.1080/21604851.2026.2646492 · Cited by 6
Ali, S. H., Lee, M. K., Tan, X. Q., Wong, C. J., Magkos, F., Ang, I. Y. H., & Toh, S.-A. E. S. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02062-x · Cited by 2
Lisco, G., Tullio, A. D., Disoteo, O., Dicorato, P., Tortora, A., Geronimo, V. D., & Triggiani, V. (2026) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-026-10033-w · Cited by 1
“In addition to promoting weight loss, incretin-based therapies have been shown to reduce the burden of obesity-related complications from metabolic [147], cardiovascular [148], and renal perspectives [149].”
Glucagon-Like Peptide-1 Receptor Agonists: Their Potential Role in Prediabetes
Panou, T., Gouveri, E., Popovic, D. S., Papazoglou, D., & Παπάνας, Ν. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01865-5 · Cited by 2
Adamidis, N., Margariti, T., Georgakopoulou, V., Adamidi, S., Desalermos, A. P., Kyventidou, M., Koutrakos, T., Bouros, D. E., Papadopoulou, N., & Adamidis, S. (2026) · Cureus · doi:10.7759/cureus.107081 · Cited by 3
Mitropoulou, P., Prokšelj, K., Janež, A., Gil, F. R., Verma, S., Jurić, I., Vida, V. L., Gatzoulis, M. Α., & Brida, M. (2026) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcag067 · Cited by 3
“77,78 In SURMOUNT-5, tirzepatide outperformed high-dose semaglu-tide (20.2% vs. 13.7% weight loss at 72 weeks) 79 A recent meta-analysis supported tirzepatide as the most effective current anti-obesity pharmacotherapy.”
InfluentialGalindo, R. J., Aronne, L. J., Horn, D. B., Miras, A. D., Dunn, J. P., Cao, D., Lee, C. J., Karanikas, C. A., Heine, R. J., Falcón, B. L., et al. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02895-3 · Cited by 3
“…semaglutide for improved, albeit modest, glycemic control, and improved body weight-related parameters and anthropometric indices are consistent with those reported in the respective placebo-controlled studies of tirzepatide and semaglutide among individuals with obesity and prediabetes [ 9 , 10 ].”
InfluentialSelf-citationTirzepatide attenuates lipopolysaccharide-induced acute lung injury via AMPK/NF-κB signaling pathway
Zhang, Y., & Li, L. (2026) · Tissue and Cell · doi:10.1016/j.tice.2026.103557 · Cited by 1
GLP-1 Receptor Agonists: Therapeutic Potential and Emerging Concerns
Nowak, K., Łupina, K., Kalisz, A., Ilkiewicz, Ł., & Janczura, J. (2026) · Current Pharmacology Reports · doi:10.1007/s40495-026-00459-w · Cited by 2
Pearson, M. J., Willency, J. A., Lin, Y., Abadi, A., Hartman, M. L., Coşkun, T., Ruotolo, G., Duffin, K. L., Haupt, A., Newgard, C. B., et al. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag201
Olchanski, N., Skiro, C. E., Sonon, K. E., Kaus, S. J., Holmstrand, E. C., Ciemins, E. L., Cuddeback, J. K., Colangelo, F. R., & Kent, D. M. (2026) · Learning Health Systems · doi:10.1002/lrh2.70087 · Cited by 1
“Recently, the SURMOUNT-1 trial added a third evidence-based intervention, showing that taking tirzepatide dramatically reduces the risk of developing diabetes among people with prediabetes and obesity (hazard ratio 0.07 at 40 months, p 0.001) [7].”
InfluentialMalhotra, A., Gottlieb, D. J., Kundel, V., Woehrle, H., Chakladar, S., GONCALVES, L. F., & Calamai, G. (2026) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2026.101660 · Cited by 3
“Longer-term evaluations would be valuable, especially in light of the three-year SURMOUNT-1 follow-up results, which showed durable benefits of tirzepatide, including a marked reduction in diabetes incidence [58].”
Khan, I., Meenakshi, S., Abubakar, M., Kumar, N., Gaikwad, V. L., Rai, A., & Murti, K. (2026) · Endocrine · doi:10.1007/s12020-026-04686-5 · Cited by 2
“The SURMOUNT-3 and SURMOUNT-4 trials emphasize tirzepatide’s role in boosting lifestyle-related weight loss and supporting long-term weight maintenance, indicating it remains effective with ongoing therapy [228].”
Li, L., Shui, D., Zhang, X., Tan, B., & Deng, Y. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1854779 · Cited by 2
“Subgroup analyses were performed according to study drug. substantially among studies (29, 30).”
Medical treatments for obesity: what does the future have in store?
Bassatne, A., & Rizo, I. M. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag274 · Cited by 1
New directions in childhood obesity treatment – A path forward or wishful thinking?
Reilly, J. L., Arora, S., Chatman, K., Cooper, Z., & Hsia, D. S. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.05.010 · Cited by 1
Ntelis, S., & Wojeck, B. S. (2025) · Current Hypertension Reports · doi:10.1007/s11906-025-01349-0 · Cited by 1
“After long-term treatment of 176 weeks, the rate of diabetes diagnosis was 93% lower with tirzepatide compared to placebo (HR, 0.07; 95% CI, 0.0 to 0.1) [39].”
InfluentialMcCartney, F. (2025) · Therapeutic Delivery · doi:10.1080/20415990.2025.2469483 · Cited by 1
Huang, S. Y., Farber‐Eger, E. H., Tamaroff, J. G., et al. (2025) · medRxiv · doi:10.1101/2025.02.21.25322699 · Cited by 1
Development and Validation of a Simple Model to Predict Patient HeightPreprint
Moin, E. E., Seewald, N. J., & Halpern, S. D. (2025) · medRxiv · doi:10.1101/2025.03.12.25323846 · Cited by 1
“7,8 Body mass index (BMI), a function of height and weight, is even more widely used, with applications in arenas as diverse as allocation of transplant organs, 9 indications for medications like glucagon-like peptide-1 receptor agonists, 10,11 and screening for risk of cardiovascular disease.”
Budini, B., Luo, S., Tam, M., Stead, I., Lee, A. S., Akrami, A., Vidal‐Puig, A., & Park, A. (2025) · medRxiv · doi:10.1101/2025.06.09.25328726 · Cited by 1
Levine, J., Lee, Y. A., Pham, A. K., Guo, J. S., Dai, H., Radwan, R. M., Bian, J., Novikov, A. A., & Sheer, A. (2025) · medRxiv · doi:10.1101/2025.11.13.25340005 · Cited by 2
Equity, diversity and inclusion is essential for rigorous science and good for health
Pritlove, C., Herder, C., Krook, A., et al. (2025) · Metabologia · doi:10.1007/s44357-025-00001-3 · Cited by 1
Ciudin, A., Baker, J. L., Belančić, A., Busetto, L., Diker, D., Fábryová, Ľ., Frühbeck, G., Goossens, G. H., Gordon, J., Monami, M., et al. (2026) · medRxiv · doi:10.64898/2026.04.19.26351196 · Cited by 1
Halimi, S. (2025) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2024.12.008
Adipositastherapie und Diabetesprävention mit Tirzepatid
Schürfeld, R. (2025) · Die Diabetologie · doi:10.1007/s11428-025-01295-0
“In der vorgestelltenStudieSURMOUNT-1wurden die Wirksamkeit und Sicherheit von Tirze-patid bei Personen mit Übergewicht ohne Diabetes mellitus untersucht [1].”
Therapie-Update bei Adipositas
Gallwitz, B. (2025) · Info Diabetologie · doi:10.1007/s15034-024-5057-0
Integrating social determinants of health into global approaches to early-onset type 2 diabetes
Seo, J., Rizzo, M., & Powell‐Wiley, T. M. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.108982
Medikamentöse Therapie der Adipositas bei Kindern und Jugendlichen
Lischka, J., Torbahn, G., Mörwald, K., Gomahr, J., Jabbour, J., Geiersberger, S., & Weghuber, D. (2025) · Monatsschrift Kinderheilkunde · doi:10.1007/s00112-025-02149-1 · Cited by 1
“Tirzepatid (5, 10 und 15mg tgl.) erzielte im Vergleich zu anderen GLP1-RA, wie Se-maglutid, eine stärkere Gewichtsabnahme bei einem ähnlichen Sicherheitsprofil bei Erwachsenen[27,28].”
Kudaiberdieva, G. (2025) · Heart Vessels and Transplantation · doi:10.24969/hvt.2025.551
Pedicino, D., & Liuzzo, G. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf236
Miller, C. K., Young-Hyman, D. L., Wooldridge, J. S., Piatt, G., & Hawkins, J. (2025) · Clinical Diabetes · doi:10.2337/cd25-0020 · Cited by 1
Tirzepatid-Therapie senkt Risiko für Typ-2-Diabetes bei Adipositas
Lellis, M. A. D. (2025) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-2510-0085
Del metabolismo a la piel: GLP-1 y su potencial en hidradenitis supurativa
Elices, D. G., Martínez, M. L. G., Sanabria, M. R., et al. (2025) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2025.102524
Aberle, J. (2025) · Die Diabetologie · doi:10.1007/s11428-025-01336-8 · Cited by 1
Recent advances in the pharmacological treatment of obesity
Nam, G. E. (2025) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0058 · Cited by 1
Tirzepatid zur Adipositasbehandlung und Diabetesprävention
Manekeller, S. (2025) · Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie · doi:10.1055/a-2569-8292
Gewichtsreduktion mit Inkretinmimetika – Chancen und Risiken
Zech, T., Kirchweger, B., & Fürst, R. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01918-0
The need to address the risk of osteosarcopenia induced by tirzepatide therapy
Mattia, G. D., & Mazzantini, M. (2025) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/el8zor
“…receptor agonist, was able to induce weight loss in the range of -15.0% to -20.9%, depending on the administered dose, at 72 weeks (1), and more recently, the Investigators reported that tirzepatide therapy was safe and efficacious at lowering progression to type 2 diabetes after three years (2).”
InfluentialInsulin Prevents Fat Loss and Promotes Muscle Loss During Intermittent Fasting in ObesityPreprint
Marko, D. M., Conn, M. O., Cavallari, J. F., Neudorf, H., Steele, A. P., Duggan, B. M., McAlpin, B. T., Barra, N., Hawke, T., Little, J. P., et al. (2025) · bioRxiv · doi:10.1101/2025.06.21.660875
Tirzepatide: The Most Effective Drug Therapy for Prevention of Type 2 Diabetes
Mikhail, N. (2025) · Clinical Endocrinology and Metabolism · doi:10.31579/2834-8761/073
Proposal for a Value-Based Agreement to Reimburse Anti-obesity Medicines in Traditional MedicarePreprint
Ward, A. S., Trish, E. E., Goldman, D. P., & Lakdawalla, D. (2025) · medRxiv · doi:10.1101/2025.07.10.25331289 · Cited by 1
Drug–drug interactions between tirzepatide and antiretrovirals: time to reassess and reassure?
Poloni, A., Cattaneo, D., Giacomelli, A., Gori, A., Ridolfo, A. L., & Gervasoni, C. (2025) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaf245
Giandalia, A., & Cucinotta, D. (2025) · L Endocrinologo · doi:10.1007/s40619-025-01663-4
“…1 Dipartimento di Medicina Clinica e Sperimentale, Università di Messina, Messina, Italia approvato per il trattamento dell’obesità, il duplice agonista recettoriale GLP1-GIP tirzepatide, si è dimostrato efficace nel prevenire il DM2 in soggetti obesi con prediabete [7].”
Clinical perspective on non-sleepy obstructive sleep apnea; to treat or not to treat?
Luu, S., Nanayakkara, B., & Yee, B. J. (2025) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2025.2539542
“…liraglutide and tirzepatide have demonstrated cardiometabolic benefits, including resolution of metabolic dysfunction-associated steatohepatitis [127,128], reduced risk of cardiovascular death or worsening heart failure [129,130], and prevention of progression to type 2 diabetes mellitus [131,132].”
Vienghirun, J., Sawangjit, R., Suttiruksa, S., Chaiyakunapruk, N., Jinathongthai, P., Khunti, K. K., & Lee, S. W. H. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5372118
Tirzepatide Heralds the Hope of Chronic Disease Eradication
Tchang, B. G., Barenbaum, S. R., & Aronne, L. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf444
Self-citationTirzepatid zur Adipositasbehandlung und Diabetesprävention
Manekeller, S. (2025) · Allgemein- und Viszeralchirurgie up2date · doi:10.1055/a-2622-7796
Treat the Weight, Lower the Pressure
Sattar, N. A., & Delles, C. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.07.059
Emerging Therapeutic Agents for Obesity and Future Perspectives
Otoda, T. (2025) · Journal of Nihon University Medical Association · doi:10.4264/numa.84.4_185
Metadata
- Authors
- Jastreboff, A. M., le Roux, C. W., Stefanski, A., Aronne, L. J., Halpern, B., Wharton, S., Wilding, J. P. H., Perreault, L., Zhang, S., Battula, R., Bunck, M. C., Ahmad, N. N., & Jouravskaya, I.
- Affiliations
- University College Dublin (IE)
- Eli Lilly, Indianapolis
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2025-03-06
- Volume
- 392
- Issue
- 10
- Pages
- 958-971
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4404310616
- Semantic Scholar
- 6522eecd15e4fbb48021d492e79ee341ffc3540a
- Cited by
- 462
- References
- 41
- Citations by year
- 2026: 239 · 2025: 220
- FWCI
- 130.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Keywords
- tirzepatide, obesity, prediabetes, type 2 diabetes prevention, weight loss, GIP/GLP-1 receptor agonist, long-term safety, diabetes onset, adverse events, drug discontinuation
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Adult, Body Weight, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Double-Blind Method, Female, Gastrointestinal Diseases, Humans, Male, Middle Aged, Obesity, Prediabetic State, Weight Loss, Disease Progression, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.